Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)

Molecular Pharmacology

Volumn 62, Issue 3, 2002, Pages 608-617

  Gagné, Jean François ^a   Montminy, Valerie ^a   Belanger, Patrick ^a   Journault, Kim ^a   Gaucher, Genevieve ^a   Guillemette, Chantal ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; DRUG METABOLITE; ENZYME VARIANT; FLAVOPIRIDOL; GLUCURONIC ACID; GLUCURONIDATE; GLUCURONOSYLTRANSFERASE; IRINOTECAN; ISOENZYME; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; CORRELATION COEFFICIENT; DNA POLYMORPHISM; DNA SEQUENCE; DRUG CLEARANCE; DRUG GLUCURONIDATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME MECHANISM; FEMALE; GASTROINTESTINAL SYMPTOM; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS;

CAMPTOTHECIN; CATALYSIS; CELLS, CULTURED; GLUCURONATES; GLUCURONOSYLTRANSFERASE; HUMANS; ISOENZYMES; MICROSOMES, LIVER; POLYMORPHISM, GENETIC; RECOMBINANT PROTEINS;

EID: 0036765309     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.62.3.608     Document Type: Article

References (40)

1. Akaba K, Kimura T, Sasaki A, Tanabe S, Ikegami T, Hashimoto M, Umeda H, Yoshida H, Umetsu K, Chiba H, Yuasa I, and Hayasaka K (1998) Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphateglucuronosyltransferase gene: a common mutation among Japanese, Korens and Chinese. Biochem Mol Biol Int 46:21-26.
2. Akaba K, Kimura T, Sasaki A, Tanabe S, Wakabayashi T, Hiroi M, Yasumura S, Maki K, Aikawa S, and Hayasaka K (1999) Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese. J Hum Genet 44:22-25.
3. Albert C, Valiée M, Beaudry G, Bélanger A, and DW Hum (1999) The monkey and human uridine diphosphate-glucuronosyltransferase UGT1A9, expressed in steroid target tissues, are estrogen-conjugating enzymes. Endocrinology 140:3292-3302.
4. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, and Hasegawa Y (2000) Polymorphisms of UDP-gluc-uronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60: 6921-6926.
5. Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, and Kamataki T (1998) UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 9:845-847.
6. Aono S, Yamada Y, Keino H, Hanada N, Nakagawa T, Sasaoka Y, Yazawa T, Sato, and Koiwai HO (1993) Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler-Najjar syndrome type II. Biochem Biophys Res Commun 197:1239-1244.
7. Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, and Hoshi A (1993) Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 84:697-702.
8. Ciotti M, Basu N, Brangi M, and Owens I (1999) Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun 260:199-202.
9. Ciotti M, Marrone A, Potter C, and Owens IS (1997) Genetic polymorphism in the human UGT1A6 UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics 7:485-495.
10. Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO, and Mackenzie PI (2001) Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 299:998-1006.
11. Cunningham D, Maroun J, Vanhoefer U, and Van Cutsem E (2001) Optimizing the use of irinotecan colorectal cancer. Oncologist 6(Suppl 4):17-23.
12. Fisher MB, Campanale K, Ackermann BL, VandenBranden M, and Wrighton SA (2000) In vitro glucuronidation using human liver microsomes and the poreforming peptide alamethicin. Drug Metab Dispos 28:360-566.
13. Gong QH, Cho JW, Huang T, Potter C, Gholami N, Basu NK, Kubota S, Carvalho S, Pennington MW, Owens IS, and Popescu NC (2001) Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 11:337-368.
14. Guillemette C, Lévesque É, Beaulieu M, Turgeon D, Hum WD, and Bélanger A (1997) Differential regulation of two UDP-glucuronosyltransferases, UGT2B15 and UGT2B17, in human prostate LNCaP cells. Endocrinology 138:2998-3005.
15. Guillemette C, Ritter JK, Auyeung DJ, Kessler FK, and Housman DE (2000) Structural heterogeneity at the UDP-glucuronosyltransferase 1A locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 10:629-644.
16. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, and Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54:3723-3725.
17. Gupta E, Mick R, Ramirez J, Wang X, Lestingi TM, Vokes EE, and Ratain MJ (1997) Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 15:1502-1510.
18. Hagenauer B, Salamon A, Thalhammer T, Kunert O, Haslinger E, Klingler P, Senderowicz AM, Sausville EA, and Jager W (2001) In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDF-glucuronosyltransferases 1A1 and 1A9. Drug Metab Dispos 29:407-414.
19. Iyer L (1999) Inherited variations in drug-metabolizing enzymes: significance in clinical oncology. Mol Diagn 4:327-333.
20. Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S, Di Rienzo, and Ratain MJ (1999) Phenotype genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65:576-582.
21. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephiy TR, Coffman BL, and Ratain MJ (1999) Genetic predisposition to the motabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-39) in human liver microsomes. J Clin Invest 101:847-854.
22. Kawato Y, Aonuma M, Hirota Y, Kuga H, and Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191.
23. Kudoh S, Fukuoka M, Masuda N, Yoshikawa A, Kusunoki Y, Matsui K, Negoro S, Takifuji N, Nakagawa K, Hirashima T, et al. (1995) Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. Jpn J Concur Res 86:406-413.
24. Levesque E, Turgeon D, Carrier JS, Montminy V, Beaulieu M, and Belanger A (2001) Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP glucuronosyltransferase. Biochemistry 40:3869-3881.
25. Lokiec F, du Sorbier BM, and Sanderink GJ (1996) Irinotecan (CPT-11) metabolites in human bile and urine. Clin Cancer Res 2:1943-1949.
26. Mackenzie PI, Owens IS, Burchell B, Book KW, Bairoch A, Bélanger A, Fournel-Gigleux S, Green M, Hum DW, Iyanagi T, et al. (1997) The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7:255-269.
27. Mani S (2001) UGT1A1 polymorphism predicts irinotecan toxicity: evolving proof. AAPS Pharm Sci 3:2.
28. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, and Sparrebeom A (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7:2182-2194.
29. Ramirez J, Iyer L, Journault K, Bélanger P, Innocenti F, Ratain M, and Guillemette C (2002) In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Pharm Res 19:588-594.
30. Ratain MJ (2002) Irinotecan dosing: does the C PT in CPT-11 stand for "Can't Predict Toxicity"? J Clin Oncol 20:7-8.
31. Riedy M, Wang JY, Miller AP, Buckler A, Hall J, and Guida M (2000) Genomic organization of the UGT2b gene cluster on human chromosome 4q13. Pharmcogenetics 10:251-260.
32. Rivory LP and Robert J (1994) Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11 and its metabolite SN-38 in plasma. J Chromatogr B Biomed Appl 661:133-141.
33. Rothenberg ML (1998) Efficacy and toxicity of irinotecan in patients with colorectal cancer. Semin Oncol 25:39-46.
34. Rothenberg ML (2001) Irinotecan (CPT-11): recent developments and future direction-colorectal cancer and beyond. Oncologist 6:66-80.
35. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914.
36. Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L, Elfring GL, Locker PK, and Miller LL (2001) Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 6:81-91.
37. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression and disease. Annu Rev Pharmacol Toxicol 40:581-616.
38. Turgeon D, Carrier J, Levesque E, Hum DW, and Belanger A (2001) Relative enzymatic activity, protein stability and tissue distribution of human steroidmetabolizing UGT2B subfamily members. Endocrinology 142:778-787.
39. Turgeon D, Carrier JS, Levesque E, Beatty BG, Belanger A, and Hum DW (2000) Isolation and characterization of the human UGT2B15 gene, localized within a cluster of UGT2B genes and pseudogenes on chromosome 4. J Mol Biol 295:489-504.
40. Vogel A, Kneip S, Barut A, Ehmer U, Tukey RH, Manns MP, and Strassburg CP (2001) Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. Gastroenterology 121:1136-1144.